Biomerica Inc (BMRA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Biomerica Inc stock (BMRA) is currently trading at $2.16. Biomerica Inc PS ratio (Price-to-Sales) is 1.48. Analyst consensus price target for BMRA is $13.00. WallStSmart rates BMRA as Sell.
- BMRA PE ratio analysis and historical PE chart
- BMRA PS ratio (Price-to-Sales) history and trend
- BMRA intrinsic value — DCF, Graham Number, EPV models
- BMRA stock price prediction 2025 2026 2027 2028 2029 2030
- BMRA fair value vs current price
- BMRA insider transactions and insider buying
- Is BMRA undervalued or overvalued?
- Biomerica Inc financial analysis — revenue, earnings, cash flow
- BMRA Piotroski F-Score and Altman Z-Score
- BMRA analyst price target and Smart Rating
Biomerica Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Biomerica Inc (BMRA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Biomerica Inc (BMRA) Key Strengths (2)
Paying $1.48 for every $1 of annual revenue
Trading at 1.49x book value, attractively priced
Supporting Valuation Data
Biomerica Inc (BMRA) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -23.60%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 2.37%
Micro-cap company with very limited liquidity and high volatility
Biomerica Inc (BMRA) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (1.48), Price/Book (1.49) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -23.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -69.60%, Operating Margin at -81.00%, Profit Margin at -74.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -69.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -23.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BMRA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BMRA's Price-to-Sales ratio of 1.48x sits near its historical average of 1.4x (71th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 2% below its historical high of 1.51x set in Mar 2026, and 14% above its historical low of 1.3x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Biomerica Inc (BMRA) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Biomerica Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 5M with 24% decline year-over-year. The company is currently unprofitable, posting a -74.8% profit margin.
Key Findings
Debt-to-equity ratio of 0.06 indicates a conservative balance sheet with 3M in cash.
Revenue contracted 24% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -74.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Biomerica Inc.
Bottom Line
Biomerica Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:50:07 AM
About Biomerica Inc(BMRA)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology company specializing in the development and manufacturing of cutting-edge diagnostic solutions across the medical and food sectors. With a strong focus on proprietary testing methods for managing metabolic diseases, gastrointestinal disorders, and food intolerances, Biomerica is committed to improving healthcare outcomes. The company actively engages in strategic research collaborations, positioning itself to address critical unmet medical needs and harness growth opportunities in the rapidly evolving diagnostics landscape. Leveraging technological advancements and a patient-centered approach, Biomerica is well-positioned to lead transformational changes in global healthcare diagnostics.